摘要食管癌在中国发病率高,死亡率在癌症死亡率中常年居于第四位.在老龄化社会中,老年食管癌患者数量持续增加.然而,由于并发症多、一般行为评分低、治疗耐受性差等临床特点,很多研究将老年食管癌患者排除在外.尽管在过去的几十年中,食管癌预后有所改善,但老年食管癌的治疗效果并不理想.这需要联合现有治疗手段并结合新的治疗方式.文中分析了放疗及放疗联合化疗、靶向治疗或免疫治疗在不可手术老年食管癌患者中的疗效及不良反应.

abstractsAs the fourth leading cause of cancer death for years,esophageal carcinoma yields a high morbidity in China. In an aging society,the quantity of elderly patients with esophageal carcinoma is ever increasing. However,elderly patients have been excluded in most studies due to more comorbidities,lower performance status grade,worse therapeutic tolerance and other clinical features. Although clinical prognosis of esophageal carcinoma patients has been improved in the past decades, the clinical efficacy in the treatment of esophageal carcinoma in elderly patients is still unsatisfactory. Current options should be combined with novel therapeutic srategies to enhance the clinical efficacy. In this article, the clinical efficacy and adverse events of radiotherapy, radiochemotherapy, targeted therapy or immunotherapy in treating elderly patients with unresectable esophageal carcinoma were retrospectively analyzed.